Adstiladrin (nadofaragene firadenovec-vncg) prior authorization — Non‑muscle invasive bladder cancer
Customize your policy alerts
Sign up for AvMed Policy Pub. 100-2 alerts
Get alerted when Policy Pub. 100-2 changes without checking for updates manually.
Monitor payer policy activity
Requirements and clinical criteria for prior authorization of Adstiladrin (J9029) for treatment of non‑muscle invasive bladder cancer in AvMed members; intended for prescribing providers and facility staff submitting PA/step-edit requests.
No material clinical or coverage changes in this revision.
Coverage Criteria for Adstiladrin (nadofaragene firadenovec-vncg)
Initial Authorization
Covered when ALL of the following are met for initial authorization:
All lines must be met and supported by documentation.
Reauthorization
Covered when ALL of the following are met for reauthorization:
To support each line checked, all documentation including lab results, diagnostics, and/or chart notes must be provided or request may be denied.
Members must have documentation demonstrating the absence of extra‑vesical disease, muscle‑invasive disease (T2–T4), or metastatic urothelial carcinoma. Approval requires recorded workup or evaluation showing that disease is confined to the bladder (no involvement of the urethra, ureter, renal pelvis, or distant sites) and specifically that muscle‑invasive (T2–T4) or metastatic disease is NOT present.
Use of manufacturer or office samples to start Adstiladrin does not meet preauthorization or step‑edit requirements and will not be accepted as evidence that therapy was initiated. Prior therapies and treatment history will be verified through pharmacy paid claims or submitted chart notes; therefore, sample use cannot substitute for required documentation when requesting authorization.
Coding and Billing Information
| J9029 | Adstiladrin (nadofaragene firadenovec-vncg) |
| 55566-1050-01 | NDC for Adstiladrin 20 mL single-dose vial |
Provider Actions and Prior Authorization Requirements
Prior authorization required (J9029) — prescriber must sign PA form
Prior authorization is required for Adstiladrin (nadofaragene firadenovec-vncg), HCPCS J9029. The prescribing provider must complete and sign the medical prior authorization/step-edit request form (hand-signed; preprinted stamps not valid) and supply clinical documentation that supports the coverage criteria.
- Drug Requested: Adstiladrin (J9029)
- Prescribing physician must sign and clearly print name on the PA form (preprinted stamps not valid)
Samples not acceptable to meet PA/step-edit
Use of samples to initiate therapy will not satisfy preauthorization or step-edit requirements and is not acceptable documentation of prior therapy; prior treatments will be verified via pharmacy paid claims or submitted chart notes.
- Samples cannot be used to meet therapy initiation or step-edit criteria
- Previous therapies verified through pharmacy paid claims or chart notes
Required documentation to support PA
Provide the completed PA form with the prescriber's hand signature and contact information, member demographics, diagnosis, and supporting clinical documentation including workup demonstrating absence of extra‑vesical, muscle‑invasive, or metastatic disease; TURBT operative notes; BCG treatment history and response; and site/contact information for administration.
- Prescriber signature (hand-signed; preprinted stamps not valid)
- Member demographics and diagnosis (NMIBC with CIS) and documentation that excludes extra‑vesical/muscle‑invasive/metastatic disease
- TURBT operative notes and BCG treatment history/response
- Location/NPI/DEA of administering site or specialty pharmacy information
Incomplete or illegible submissions risk delay/denial
Incomplete, incorrect, or illegible information on the PA request can delay review or result in denial of authorization; ensure all required fields and legible contact information are provided.
- Ensure form is complete, correct, and legible to avoid delays or denial
Insufficient clinical documentation may cause denial
Failure to provide required supporting clinical documentation — such as lab results, diagnostic studies, chart notes, cystoscopy/TURBT/biopsy reports, and documentation of prior BCG therapy and response — may result in denial of the request.
- Include lab results, diagnostics, and chart notes as indicated for each criterion checked
- Provide cystoscopy and urine cytology results for renewals and TURBT/biopsy operative reports
- Document prior BCG courses and response per the policy definition
Definitions
Background
Adstiladrin (nadofaragene firadenovec‑vncg) is an intravesical gene therapy indicated for treatment of non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The policy expects prior transurethral resection of bladder tumor (TURBT) to remove all resectable disease and requires that the medication be used as a single‑agent intravesical instillation. Approval is limited to adults (age ≥18 years) and excludes members with hypersensitivity to interferon alfa.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.